Home
>
US Stocks
>
Black Diamond Therapeutics

Black Diamond Therapeutics (BDTX)

$2.035

+0.18

(+9.41%)▲

Live

Insights on Black Diamond Therapeutics

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 35.8%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 118.4%

Performance

  • $1.80
    $2.05
    $2.04
    downward going graph

    11.76%

    Downside

    Day's Volatility :12.2%

    Upside

    0.49%

    downward going graph
  • $1.18
    $4.08
    $2.04
    downward going graph

    42.16%

    Downside

    52 Weeks Volatility :71.08%

    Upside

    50.0%

    downward going graph

Returns

PeriodBlack Diamond TherapeuticsSector (Health Care)Index (Russel 2000)
3 Months
-1.59%
0.7%
-6.8%
6 Months
-9.71%
-8.3%
-6.0%
1 Year
10.06%
-1.9%
-4.6%
3 Years
-95.32%
25.3%
25.9%

Highlights

Market Capitalization
67.9M
Book Value
$2.69
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.57
Wall Street Target Price
6.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-31.23%
Return On Equity TTM
-63.92%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-88.2M
Diluted Eps TTM
-2.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.95
EPS Estimate Next Year
-1.75
EPS Estimate Current Quarter
-0.61
EPS Estimate Next Quarter
-0.52

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Black Diamond Therapeutics(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 219.41%

Current $2.04
Target $6.50

Technicals Summary

Sell

Neutral

Buy

Black Diamond Therapeutics is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Black Diamond Therapeutics
Black Diamond Therapeutics
16.98%
-9.71%
10.06%
-95.32%
-95.29%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Black Diamond Therapeutics
Black Diamond Therapeutics
NA
NA
NA
-1.95
-0.64
-0.31
0.0
2.69
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Black Diamond Therapeutics
Black Diamond Therapeutics
Buy
$67.9M
-95.29%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • Bellevue Group AG

    14.78%

  • NEA Management Company, LLC

    9.45%

  • RA Capital Management, LLC

    7.09%

  • Boxer Capital LLC

    5.52%

  • Artal Group S A

    4.51%

  • EcoR1 Capital, LLC

    3.26%

Corporate Announcements

  • Black Diamond Therapeutics Earnings

    Black Diamond Therapeutics’s price-to-earnings ratio stands at None

    Read More

Company Information

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine.

Organization
Black Diamond Therapeutics
Employees
65
CEO
Dr. David M. Epstein Ph.D.
Industry
Health Technology

Discover More

FAQs